197 related articles for article (PubMed ID: 16928815)
1. Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T.
Muruganandham M; Lupu M; Dyke JP; Matei C; Linn M; Packman K; Kolinsky K; Higgins B; Koutcher JA
Mol Cancer Ther; 2006 Aug; 5(8):1950-7. PubMed ID: 16928815
[TBL] [Abstract][Full Text] [Related]
2. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.
Marzola P; Degrassi A; Calderan L; Farace P; Nicolato E; Crescimanno C; Sandri M; Giusti A; Pesenti E; Terron A; Sbarbati A; Osculati F
Clin Cancer Res; 2005 Aug; 11(16):5827-32. PubMed ID: 16115922
[TBL] [Abstract][Full Text] [Related]
3. Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors.
Hillman GG; Singh-Gupta V; Zhang H; Al-Bashir AK; Katkuri Y; Li M; Yunker CK; Patel AD; Abrams J; Haacke EM
Neoplasia; 2009 Sep; 11(9):910-20. PubMed ID: 19724685
[TBL] [Abstract][Full Text] [Related]
4. Anti-angiogenic Effects of Bumetanide Revealed by DCE-MRI with a Biodegradable Macromolecular Contrast Agent in a Colon Cancer Model.
Malamas AS; Jin E; Zhang Q; Haaga J; Lu ZR
Pharm Res; 2015 Sep; 32(9):3029-43. PubMed ID: 25840948
[TBL] [Abstract][Full Text] [Related]
5. In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model.
Marzola P; Degrassi A; Calderan L; Farace P; Crescimanno C; Nicolato E; Giusti A; Pesenti E; Terron A; Sbarbati A; Abrams T; Murray L; Osculati F
Clin Cancer Res; 2004 Jan; 10(2):739-50. PubMed ID: 14760097
[TBL] [Abstract][Full Text] [Related]
6. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
7. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
Wilmes LJ; Pallavicini MG; Fleming LM; Gibbs J; Wang D; Li KL; Partridge SC; Henry RG; Shalinsky DR; Hu-Lowe D; Park JW; McShane TM; Lu Y; Brasch RC; Hylton NM
Magn Reson Imaging; 2007 Apr; 25(3):319-27. PubMed ID: 17371720
[TBL] [Abstract][Full Text] [Related]
8. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
[TBL] [Abstract][Full Text] [Related]
9. Integrin αvβ3-targeted dynamic contrast-enhanced magnetic resonance imaging using a gadolinium-loaded polyethylene gycol-dendrimer-cyclic RGD conjugate to evaluate tumor angiogenesis and to assess early antiangiogenic treatment response in a mouse xenograft tumor model.
Chen WT; Shih TT; Chen RC; Tu SY; Hsieh WY; Yang PC
Mol Imaging; 2012; 11(4):286-300. PubMed ID: 22954145
[TBL] [Abstract][Full Text] [Related]
10. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.
Nakamura K; Taguchi E; Miura T; Yamamoto A; Takahashi K; Bichat F; Guilbaud N; Hasegawa K; Kubo K; Fujiwara Y; Suzuki R; Kubo K; Shibuya M; Isae T
Cancer Res; 2006 Sep; 66(18):9134-42. PubMed ID: 16982756
[TBL] [Abstract][Full Text] [Related]
11. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as Imaging Biomarker for Vascular Normalization Effect of Infigratinib in High-FGFR-Expressing Hepatocellular Carcinoma Xenografts.
Tran A; Koh TS; Prawira A; Ho RZW; Le TBU; Vu TC; Hartano S; Teo XQ; Chen WC; Lee P; Thng CH; Huynh H
Mol Imaging Biol; 2021 Feb; 23(1):70-83. PubMed ID: 32909245
[TBL] [Abstract][Full Text] [Related]
12. Spatiotemporal heterogeneity of tumor vasculature during tumor growth and antiangiogenic treatment: MRI assessment using permeability and blood volume parameters.
Kim C; Suh JY; Heo C; Lee CK; Shim WH; Park BW; Cho G; Lee DW; Woo DC; Kim SY; Kim YJ; Bae DJ; Kim JK
Cancer Med; 2018 Aug; 7(8):3921-3934. PubMed ID: 29983002
[TBL] [Abstract][Full Text] [Related]
13. Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture.
Jiang Y; Allen D; Kersemans V; Devery AM; Bokobza SM; Smart S; Ryan AJ
Lung Cancer; 2015 Nov; 90(2):191-8. PubMed ID: 26323213
[TBL] [Abstract][Full Text] [Related]
14. Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101.
Kiessling F; Farhan N; Lichy MP; Vosseler S; Heilmann M; Krix M; Bohlen P; Miller DW; Mueller MM; Semmler W; Fusenig NE; Delorme S
Neoplasia; 2004; 6(3):213-23. PubMed ID: 15153333
[TBL] [Abstract][Full Text] [Related]
15. Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging.
Zwick S; Strecker R; Kiselev V; Gall P; Huppert J; Palmowski M; Lederle W; Woenne EC; Hengerer A; Taupitz M; Semmler W; Kiessling F
J Magn Reson Imaging; 2009 May; 29(5):1125-33. PubMed ID: 19388117
[TBL] [Abstract][Full Text] [Related]
16. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
Abdollahi A; Lipson KE; Sckell A; Zieher H; Klenke F; Poerschke D; Roth A; Han X; Krix M; Bischof M; Hahnfeldt P; Grone HJ; Debus J; Hlatky L; Huber PE
Cancer Res; 2003 Dec; 63(24):8890-8. PubMed ID: 14695206
[TBL] [Abstract][Full Text] [Related]
17. Gadopentetate dimeglumine versus ultrasmall superparamagnetic iron oxide for dynamic contrast-enhanced MR imaging of tumor angiogenesis in human colon carcinoma in mice.
de Lussanet QG; Backes WH; Griffioen AW; van Engelshoven JM; Beets-Tan RG
Radiology; 2003 Nov; 229(2):429-38. PubMed ID: 14595147
[TBL] [Abstract][Full Text] [Related]
18. Dynamic contrast-enhanced magnetic resonance imaging at 1.5 Tesla with gadopentetate dimeglumine to assess the angiostatic effects of anginex in mice.
de Lussanet QG; Beets-Tan RG; Backes WH; van der Schaft DW; van Engelshoven JM; Mayo KH; Griffioen AW
Eur J Cancer; 2004 May; 40(8):1262-8. PubMed ID: 15110892
[TBL] [Abstract][Full Text] [Related]
19. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
20. ABT-869, a multitargeted receptor tyrosine kinase inhibitor, reduces tumor microvascularity and improves vascular wall integrity in preclinical tumor models.
Jiang F; Albert DH; Luo Y; Tapang P; Zhang K; Davidsen SK; Fox GB; Lesniewski R; McKeegan EM
J Pharmacol Exp Ther; 2011 Jul; 338(1):134-42. PubMed ID: 21505059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
